BioNTech SE (BNTX) Total Debt (2018 - 2025)
BioNTech SE (BNTX) posted Total Debt of $1.5 billion for Q4 2025, up 108.16% sequentially from $698.4 million in Q3 2025, and down 37.34% YoY from $2.3 billion in Q4 2024.
BioNTech SE (BNTX) Total Debt (2018 - 2025) Analysis & Trends
BioNTech SE has reported Total Debt for 8 years, with the latest figure at $1.5 billion in Q4 2025.
- Quarterly Total Debt fell 37.34% year-over-year to $1.5 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 billion (down 37.34% YoY) and the FY2025 annual result came in at $1.4 billion, down 39.18% from the prior year.
- Total Debt advanced to $1.5 billion in Q4 2025 per BNTX's latest filing, from $698.4 million in the prior quarter.
- Over five years, Total Debt peaked at $2.3 billion in Q4 2024 and troughed at $157.2 million in Q2 2024.
- A 5-year average of $725.5 million and a median of $478.2 million in 2023 frame the typical range for Total Debt.
- The sharpest annual moves came in 2023 and 2024: Total Debt sank 78.19% in 2023, then soared 374.97% in 2024.
- Over 5 years, Total Debt stood at $1.6 billion in 2021, then sank by 48.42% to $807.2 million in 2022, then plunged by 39.49% to $488.5 million in 2023, then surged by 374.97% to $2.3 billion in 2024, then slumped by 37.34% to $1.5 billion in 2025.
- According to Business Quant data, Total Debt over the past three periods registered $1.5 billion, $698.4 million, and $164.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 1.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 409.39 Mn |
| Sep 30, 2025 | 698.39 Mn |
| Jun 30, 2025 | 164.13 Mn |
| Mar 31, 2025 | 466.41 Mn |
| Dec 31, 2024 | 1.59 Bn |
| Sep 30, 2024 | 265.33 Mn |
| Jun 30, 2024 | 157.23 Mn |
| Mar 31, 2024 | 165.56 Mn |
| Dec 31, 2023 | 488.48 Mn |
| Sep 30, 2023 | 350.09 Mn |
| Jun 30, 2023 | 187.84 Mn |
| Mar 31, 2023 | 467.87 Mn |
| Dec 31, 2022 | 807.22 Mn |
| Sep 30, 2022 | 692.58 Mn |
| Jun 30, 2022 | 861.43 Mn |
| Mar 31, 2022 | 1.55 Bn |
| Dec 31, 2021 | 1.57 Bn |
| Mar 31, 2021 | 397.09 Mn |
| Dec 31, 2020 | 363.77 Mn |
| Dec 31, 2019 | 87.73 Mn |